Announcements
Excerpt from the Press Release: Zygel™ (ZYN002) achieved statistically significant and clinically meaningful improvements from baseline in multiple efficacy assessments and was generally well-tolerated through 38 weeks of treatment in INSPIRE, a Phase 2 trial with Zygel in children and adolescents with 22q11.2 deletion syndrome (22q) Devon, PA, September 14, 2023 – Zynerba Pharmaceuticals, Inc.…
Read More
Two-Part Design Provides Optionality for Interim Analysis in First Half of 2024 Full Data Readout Expected in the Second Half of 2024 Excerpt from the Press Release: BOSTON, Sept. 15, 2023 /PRNewswire/ — NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company on a quest to transform cardiometabolic diseases, today announced dosing of the first…
Read More
OICR is hosting Jayson Pomfret as part of a unique summer internship program. Excerpt from the Press Release: Jayson Pomfret understands that meaningful cancer research happens in the community as well as at the lab bench. Pomfret is an undergraduate student in Queen’s University’s Bachelor of Health Sciences program who wants to pursue a career…
Read More
Christopher Kata and the TrialStat team are exhibiting at this years DPHARM meeting on September 20th through the 22nd in booth #116. If you’re attending be sure to to reach out to Christopher to schedule a one on meeting or just drop by booth #116 at your convenience! We’re looking forward to providing live, personalized…
Read More
– Interim analysis of masked data shows EYP-1901 is well tolerated with no reported drug-related ocular or systemic serious adverse events in Phase 2 PAVIA clinical trial in non-proliferative diabetic retinopathy – – Updated interim analysis of masked safety data of Phase 2 DAVIO 2 trial in wet AMD continues to show a positive safety…
Read More
Company to present BDTX-1535 dose escalation data in NSCLC at the AACR-NCI-EORTC Conference in October 2023 Excerpt from the Press Release: CAMBRIDGE, Mass. and NEW YORK, Sept. 11, 2023 (GLOBE NEWSWIRE) — Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage precision oncology company developing therapies that target families of oncogenic mutations in patients with genetically…
Read More
Alignment with U.S. FDA on design of Phase 2/3 registrational trial, to be initiated in 1Q 2024 Innovative study design allows for potential accelerated approval in untreated (first-line) and previously treated (second-line plus) metastatic bladder cancer Conference call and webcast today at 8 a.m. ET Excerpt from the Press Release: CAMBRIDGE, England & BOSTON–(BUSINESS WIRE)–Bicycle…
Read More
− Topline Results for TAK-279 Show that a Significantly Greater Proportion of Psoriatic Arthritis Patients Achieved at Least an ACR20 Response Compared to Placebo at Week 121 − Based on the Positive Results, Takeda Intends to Initiate a Phase 3 Study of TAK-279 in Psoriatic Arthritis − Full Clinical Results Will be Presented at an…
Read More
Christopher Kata and the TrialStat team are exhibiting at this years DPHARM meeting on September 20th through the 22nd in booth #57. If you’re attending be sure to to reach out to Christopher to schedule a one on meeting or just drop by booth #57 at your convenience! We’re looking forward to providing live, personalized…
Read More
Excerpt from the Press Release: MOUNTAIN VIEW, Calif.–(BUSINESS WIRE)–Two-year results from FISH&CHIPS, a real world, multi-center, retrospective clinical study with 90,553 patients conducted by the National Health Service (NHS) England were presented at the 2023 European Society of Cardiology (ESC) Congress meeting in Amsterdam by Principal Investigator, Dr. Tim Fairbairn, Consultant Cardiologist, Liverpool Heart and Chest Hospital. FFRCT (CCTA-derived Fractional…
Read More